Neurosense Therapeutics Ltd (NASDAQ:NRSN) — Stock Price
Neurosense Therapeutics Ltd (NASDAQ:NRSN) is currently trading at $0.48 USD, down 3.14% today. Over the past 52 weeks, shares have ranged between $0.47 and $1.36. This page tracks Neurosense Therapeutics Ltd's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see NRSN stock market capitalisation.
Neurosense Therapeutics Ltd (NRSN) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Neurosense Therapeutics Ltd's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Neurosense Therapeutics Ltd Income Statement — Revenue, Profit & Earnings by Year
Neurosense Therapeutics Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | — | $22.00K | $97.00K | $89.00K | $3.00K |
| Gross Profit | — | $-22.00K | $-97.00K | $-89.00K | $-3.00K |
| Research & Development | $6.23 Million | $5.70 Million | $7.27 Million | $6.42 Million | $3.08 Million |
| SG&A | $4.86 Million | $4.20 Million | $4.78 Million | $7.14 Million | $2.50 Million |
| Total Operating Expenses | $11.09 Million | $9.90 Million | $12.05 Million | $13.46 Million | $5.59 Million |
| Operating Income | $-11.09 Million | $-9.90 Million | $-12.05 Million | $-13.55 Million | $-5.59 Million |
| EBITDA | $-11.11 Million | $-9.88 Million | $-9.64 Million | $-12.23 Million | $-2.88 Million |
| EBIT | $-11.12 Million | $-9.90 Million | $-9.66 Million | $-12.32 Million | $-2.89 Million |
| Interest Expense | — | $311.00K | $550.00K | $15.00K | $1.15 Million |
| Income Before Tax | $-11.12 Million | $-10.21 Million | $-10.11 Million | $-12.34 Million | $-4.04 Million |
| Income Tax Expense | — | — | $-1.00 | $-1.14 Million | $-1.55 Million |
| Net Income | $-11.12 Million | $-10.21 Million | $-10.11 Million | $-12.34 Million | $-4.04 Million |
Neurosense Therapeutics Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Neurosense Therapeutics Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $1.03 Million | $4.58 Million | $3.19 Million | $7.71 Million | $11.43 Million |
| Total Current Assets | $778.00K | $4.40 Million | $2.92 Million | $7.38 Million | $11.41 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | $0.00 | $3.55 Million | $0.00 |
| Net Receivables | $33.00K | $164.00K | $166.00K | $131.00K | $178.00K |
| Inventory | — | — | — | $-3.68 Million | $-178.00K |
| Property, Plant & Equipment | — | — | — | — | $19.00K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $2.59 Million | $1.99 Million | $4.94 Million | $2.09 Million | $2.42 Million |
| Total Current Liabilities | $2.52 Million | $1.99 Million | $3.46 Million | $1.73 Million | $597.00K |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $4.00K | $-3.31 Million | $-2.50 Million | $-3.33 Million | $-9.23 Million |
| Total Stockholder Equity | $-1.56 Million | $2.58 Million | $-1.76 Million | $5.62 Million | $9.01 Million |
| Retained Earnings | $-47.78 Million | $-36.66 Million | $-26.12 Million | $-20.79 Million | $-8.45 Million |
Neurosense Therapeutics Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Neurosense Therapeutics Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-7.67 Million | $-10.13 Million | $-8.35 Million | $-7.59 Million | $-1.54 Million |
| Capital Expenditures | $8.00K | $3.00K | $29.00K | $70.00K | $17.00K |
| Free Cash Flow | $-7.68 Million | $-10.14 Million | $-8.38 Million | $-7.66 Million | $-1.56 Million |
| Investing Cash Flow | $-8.00K | $1.00K | $3.47 Million | $-3.54 Million | $-17.00K |
| Financing Cash Flow | $4.43 Million | $10.91 Million | $3.98 Million | $3.69 Million | $11.90 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $2.14 Million | $557.00K | $1.54 Million | $5.11 Million | $4.16 Million |
| Depreciation | $16.00K | $22.00K | $21.00K | $89.00K | $3.00K |
| Change in Cash | $-3.21 Million | $738.00K | $-903.00K | $-7.52 Million | $10.36 Million |
Neurosense Therapeutics Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Neurosense Therapeutics Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jun 30, 2026 | 0.00 | -0.04 | +100.00% |
| Mar 25, 2026 | 0.00 | -0.11 | +100.00% |
| Nov 26, 2025 | -0.04 | -0.06 | +27.27% |
| Aug 01, 2025 | -0.19 | -0.23 | +15.56% |
| Apr 07, 2025 | -0.06 | -0.15 | +60.00% |
| Dec 31, 2024 | -0.06 | -0.15 | +60.00% |
| Dec 18, 2024 | -0.11 | -0.11 | +0.00% |
| Aug 28, 2024 | -0.05 | -0.19 | +72.97% |